Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept study, single-dose, cross-over, comparative bioavailability of AQS-1303 (transdermal doxylamine/pyridoxine long-acting patch), for the treatment of nausea and vomiting of pregnancy (NVP)

Next Previous
X
Search
Trial Profile

A proof-of-concept study, single-dose, cross-over, comparative bioavailability of AQS-1303 (transdermal doxylamine/pyridoxine long-acting patch), for the treatment of nausea and vomiting of pregnancy (NVP)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxylamine/pyridoxine (Primary) ; Doxylamine/pyridoxine
  • Indications Nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Aequus Pharmaceuticals

    • Most Recent Events

    • 27 Aug 2018 According to an Aequus Pharmaceuticals media release, company received positive feedback from a pre-Investigational Drug Application (pre-IND) meeting with the US Food and Drug Administration, the FDA agreed that AQS1303 is a suitable candidate for the 505(b)2 abbreviated regulatory pathway for approval in the United States.
    • 31 Jan 2018 According to an Aequus Pharmaceuticals media release, this study was completed in September 2017.
    • 07 Sep 2017 According to an Aequus Pharmaceuticals media release, the company will incorporate the results from this study into a pre-Investigational New Drug (pre-IND) submission with the US Food and Drug Administration (FDA) to define the clinical strategy for regulatory approval in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top